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There has been increasing interest in the development of antipro-
gestins for both anti-neoplastic and obstetrical applications
(Cadepond et al, 1997; Gravanis et al, 1985; Rocereto et al, 2000).
However, some of the progesterone antagonists can have unde-
sired agonist-like effects that are associated with cell, tissue and
species specificity. For example, RU486 has been reported to have
agonist-like activities in postmenopausal women, as well as in
numerous in vitro studies, under conditions in which inhibition
would be expected (Gravanis et al, 1985; Meyer et al, 1990;
Nordeen et al, 1993). The clinical consequences of the inappro-
priate agonist-effect of an antagonist can be grave. It is, therefore,
of clinical importance to establish appropriate experimental
models to identify the agonist-like effects, and to understand the
mechanisms by which the effects are mediated. 
Antiprogestins exert antagonistic effect by competing with pro-
gesterone for PR binding, followed by binding to progesterone
response element (PRE). Agonist-PR binding to PRE leads to
specific transcriptional responses while antagonist-occupied PR-
PRE is non-productive, resulting in the inhibition of agonist activity.
However, recent studies reveal more complex mechanisms for
antagonist-mediated gene transcription and functional activation.
Antiprogestins fall into two mechanistic classes based on their DNA
binding properties. Type I antagonist, such as ZK98299, has been
shown in vitro to fail to induce PR association with target DNA
(Klein-Hitpass et al, 1991; Bocquel et al, 1993; Truss et al, 1994).
Type II antagonist, represented by RU486, is capable of inducing
high affinity association of PR with target DNA. The DNA binding
of RU486 and other type II antagonist is often associated with
agonist activities under some circumstances (Meyer et al, 1990;
Nordeen et al, 1993; Beck et al, 1996). The presence of cell
signaling molecules such as cAMP, enhances these agonist effect
(Nordeen et al, 1993; Truss et al, 1994; Sartorius et al, 1994). More
recent studies suggest that the recruitment of corepressors or coacti-
vators into the transcription machinery also modulates the relative
agonist/antagonist activity of mixed antagonist (Jackson et al, 1997;
Simth et al, 1997; Takimoto et al, 1999). For example, coactivator
L7/SPA can enhance the partial agonist activity of RU486, whereas
the N-CoR and the related corepressor, SMRT, suppress this activity.
The net agonist activity seen with mixed antagonists has been
shown to be a function of the ratio of coactivators and corepressors. 
Studies with PR-transfected MDA-MB-231 cells (Lin et al, 1999)
revealed new aspects of RU486-mediated effects. Not only did
RU486 antagonize the effects of progesterone on focal adhesion, the
compound alone also exhibited agonist activity in that it
inhibited cell growth. Furthermore, the compound also induced
morphological and molecular changes that were distinct from pro-
gesterone-mediated effects. The PR-transfected MDA-MB-231
cells may, therefore, be used as a model system to screen for unde-
sired side effects of antiprogestins that may arise in clinical settings. 
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Summary Progesterone antagonist RU486 (mifepristone) has been implicated for many anti-neoplastic and obstetrical applications. But the
compound has demonstrated undesired agonist-like effect depending on cell, tissue and species studied. Using PR-transfected breast cancer
cells MDA-MB-231, this report describes the similarities and differences between progesterone- and RU486-mediated effects on cell growth, cell
differentiation and, at the molecular level, on the activation of p44/p42 MAP kinases (MAPK). Like progesterone, RU486 inhibited cells growth by
arresting the cells in G0/G1 phase of the cell cycle. In contrast to progesterone that induced cell spreading, RU486 induced a multipolar, stellate
morphology. RU486-treated cells showed no increase of stress fibers, nor was there any increase of focal adhesions as progesterone-treated
cells did. Furthermore, despite of the fact that both compounds inhibited cell growth, RU486 significantly stimulated the activation of p44/p42
MAP kinases whereas progesterone markedly inhibited the activation. Nonetheless, the effects of RU486 were PR-mediated and RU486 was
able to antagonize the effect of progesterone on cell growth and focal adhesion. In conclusion, RU486 can act not only as a progesterone
antagonist, a progesterone agonist but also induced morphological and molecular changes that were distinct from progesterone-mediated effects
in PR-transfected MDA-MB-231 cells. The non-progesterone-like effect of RU486 may be mediated through a pathway that is different from the
progesterone-mediated pathway, or it is the result of a blockade of certain critical step(s) in the progesterone-mediated pathway. In any case,
undesired side effects of antiprogestin may create clinical complications. PR-transfected MDA-MB-231 breast cancer cells provide a model for
studying the functions of progesterone analogues. © 2001 Cancer Research Campaign http://www.bjcancer.com 
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MATERIALS AND METHODS 
Chemicals 
Progesterone was obtained from Sigma Chemical Co (St. Louis,
MO USA). RU486 (mifepristone) and ZK98299 (onapristone)
were from Siniwest Holdings, Inc. All tissue culture plastics and
reagents were obtained from GIBCO BRL, Life Technologies, Inc. 
Cell culture 
MDA-MB-231 cells were obtained from American Tissue Culture
Collection (ATCC) in 1995 at passage 28. MDA-MB-231 cells were
cloned using 96-well plates by plating 0.5 cell/well. Clone 2 (known
as MDA-MB-231-CL2) was selected for transfection studies. All
cells were routinely maintained in phenol-red containing Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 7.5% fetal
calf serum (FCS), 2 mM glutamine and 40 mg/l gentamycin. 
Transfection 
MDA-MB-231-CL2 cells were transfected with PR expression
vectors hPR1 and hPR2 coding for PR isoform B and isoform A,
respectively, in pSG5 plasmid (Kastner et al, 1990). Vector pBK-
CMV (Stratagene) containing the neomycin-resistant gene was co-
transfected with hPR1 and hPR2. Details of transfection were
described previously (Lin et al, 1999). 
Cell growth 
Cells (2 × 104) in their late exponential growth phase were seeded
onto the 6-well plates in phenol red-free DMEM supplemented with
2 mM L-glutamine, 40 mg/l gentamycin and 5% dextran-coated
charcoal (DCC)-treated FCS (Test Medium). Treatment of FCS with
dextran-coated charcoal was to remove from FCS the endogenous
steroid hormones that may complicate the effects of progestins and
antiprogestins. Two days later, the medium was replaced with fresh
medium containing test compounds that were added from 1000-fold
stock in ethanol. This gave a final concentration of ethanol of 0.1%.
Treatment controls received 0.1% ethanol only. The medium
containing test compounds was changed every other day and the cell
numbers were determined by counting on a hemocytometer. 
DNA synthesis 
3 × 103 cells were seeded onto 96-well plates in Test Medium and
were treated with test compounds 2 days later. The effect on DNA
synthesis after 48 h treatment were measured by a ELISA kit of
bromodeoxyuridine (BrdUrd) incorporation (Boehringer Mannheim,
Germany) according to the manufacturer’s instructions. 
Cell cycle analysis by flow cytometer 
5 × 104 cells in 6-well plates were grown in Test Medium for 2
days before they were treated with the test compounds for various
time intervals. The cells were then harvested and stained with
propidium iodide (PI) in Vindelov’s (Vindelov et al, 1983) cocktail
(10 mM Tris–HCl, pH 8, 10 mM NaCl, 50 mg PI/l, and 10 mg/l
Ribonuclease A, and 0.1% Nonidet P-40) for 20 min in the dark.
The stained cells were analyzed in a FACS Calibur flow cytometer
(Becton Dickinson) with excitation wavelength of 488 nm. The
resulting histograms were analyzed by program MODFIT (Becton
Dickinson) for cell distribution in cell cycle phases. The average
coefficient of variation (CV) is within 5%.
Light microscopy 
Cells were grown in six-well plates and treated with progesterone
and its analogues alone or in combinations in 0.1% ethanol, or
0.1% ethanol for 48 h before they were viewed and photographed
under a Zeiss AXIOVERT 35 phase contrast microscope. 
Immunofluorescence microscopy 
Cells were grown on glass coverslips in six-well plates and treated
with progesterone in 0.1% ethanol or 0.1% ethanol for 48 h. After
rinsing with phosphate buffered saline (PBS), the cells were fixed
in 4% paraformaldehyde for 10 min and permeabilized with 0.2%
Triton X-100 for 10 min. This was followed by incubation with
2% fetal calf serum in PBS for 1 h to block non-specific binding.
All the subsequent incubations with Ab were carried out in PBS
containing 2% fetal calf serum. For F-actin staining, the fixed and
permeabilized cells were incubated with 10 µ g/ml FITC-phal-
loidin in PBS for 1 h at room temperature. For co-staining of 
F-actin and paxillin, Ab to paxillin were incubated with the cells
overnight at 4 ˚C, followed by incubation with FITC-conjugated
sheep anti-mouse IgG and FITC-phalloidin at room temperature
for 1 h. After washing in PBS, the coverslips were mounted on
slides with fluorescence mounting media from DAKO (USA).
Stained cells were viewed and photographed using the Zeiss
confocal laser scanning microscope model LSM 510. 
Western blotting analysis of p42/44 MAPK 
Cells (1–2 × 106) grown on 100 mm Petri dishes for 48 h before
they were treated with 0.1 µ M progesterone or 0.1 µ M RU486.
Following treatment with RU486 or progesterone, the cells were
lysed with 200 µ l cold lysis buffer (50 mM Hepes, 150 mM NaCl,
1% Triton X-100, 5 µ g/ml pepstatin A, 5 µ g/ml leupeptin, 2 µ g/ml
aprotinin, 1 mM PMSF, 100 mM sodium fluoride and 1 mM
sodium vanadate, pH 7.5). After standing on ice for 20 min, the
protein supernatants were collected by centrifugation at 13 000 g
for 20 min and the protein concentrations were determined using a
protein assay kit (BIO-RAD). 20 µ g of the protein were analyzed
by Western blotting using ECL kit (Amersham, UK). Following
detection of active p42/44 MAPK by antibody against phosphory-
lated p42/44 MAPK (New England Biolabs), the membrane was
stripped in buffer containing 62.5 mM Tris–HCl, pH 6.7, 2% SDS
and 100 mM β -mercaptoethanol for 30 min at 55 ˚C. The
membrane was re-probed with the anti-p42/p44 MAPKs Ab (New
England Biolabs) to determine the amount of total MAPK. 
Statistical analysis 
Differences between treatments were tested by Analysis of
Variance (ANOVA). Where significant differences were detected
by ANOVA, multiple comparisons among means were performed
by the least significant difference test. Correlation analysis was
performed using the program in Microsoft Excel. 
RESULTS 
ER- and PR-negative breast cancer cells MDA-MB-231-CL2 were
transfected with PR expression vectors hPR1 and hPR2 as reported1980 VC-L Lin et al
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in detail previously (Lin et al, 1999). Eight transfectant clones
expressing both PR-A and PR-B were characterized. We have
shown that progesterone-mediated effects are similar in these
clones. This report concentrates mostly on the studies obtained
with clone ABC28 that expressed 660 fmol PR per mg protein. 
RU 486 demonstrated full agonist activity in the
inhibition of cell growth of ABC28 cells 
Comprehensive studies on the effect of progesterone in the growth
of PR transfected MDA-MB-231 cells ABC28 have been previ-
ously reported (Lin et al, 1999). We have described that proges-
terone markedly inhibited the growth of ABC28 cells in a
concentration-dependent fashion. As is shown in Figure 1, Type I
antiprogestin ZK98299 alone had no effect but was able to reverse
80% of progesterone’s inhibitory effect on cell growth. In contrast,
type II antiprogestin RU486 alone showed full agonist activity in
inhibiting cell growth. Combination of RU486 with progesterone
(1 nM) resulted in the highest growth inhibitory effects that can be
achieved by either compound alone. 
The effect of RU486 on growth kinetics and cell cycle
distribution in ABC28 was similar to that of
progesterone 
The reductions in cell number of progesterone and RU486 treated
cultures were similar following 2, 4 and 6 days of treatment (Figure
2). The treated cultures were reduced to 30% of the vehicle-treated
controls after 6 days. Similar to progesterone, RU486 inhibited the
growth of ABC28 cells by arresting cells in G0/G1 phase of the cell
cycle, with a concurrent reduction in the percentage of S-phase cells
(Figure 3). The time course for progesterone and RU486 mediated
effects were almost identical. Progressive reduction of S-phase cells
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Figure 1 Effects of antiprogestins RU486 and ZK98299 alone or in
combination with progesterone on DNA synthesis in PR-transfectant clone
ABC28. The DNA synthesis was determined by ELISA of BrdUrd
incorporation. Cells (3000) were plated onto 96-well plates in phenol red-free
DMEM supplemented with 5% DCC-FCS. Test compounds-containing
medium were added to the cells two days later at various concentrations in
0.1% ethanol. BrdUrd incorporation was measured 48 h later by ELISA
according to manufacturer’s instructions. Results are the means (n = 4) of
percentage of vehicle-treated controls. The average standard error of the
means is 6.9%. Results are presented for treatment with progesterone,
RU486 or ZK98299 alone at various concentrations, or for treatment with 
1 nM progesterone (P) in the presence of various concentrations of RU486
or ZK98299 
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Figure 2 Effects of RU486 and progesterone on the growth of ABC28 cells
were compared over a 6-day period as determined by cell counting. Cells
(2 × 104) were plated onto 6-well plates in 2 ml of phenol red-free DMEM
supplemented with 5% DCC-FCS. 1 nM Progesterone or RU486-containing
medium was added to the cells two days later at various concentrations in
0.1% ethanol. The medium containing progesterone or RU486 was changed
every two days. The cell numbers were determined by counting on a
hemocytometer at 0, 2, 4, and 6 days after treatment. The results are
expressed as mean ± SEM, n = 4 
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Figure 3 Effect of RU486 and progesterone on changes in the cell cycle
distributions of PR-transfected clone ABC28. 1 × 105 cells in 6-well plates
were grown in 0.5 ml phenol red-free DMEM supplemented with 5% DCC-
FCS for 2 days before they were treated with progesterone or RU486 at 
1 nM for 24 h. The cells were then harvested and stained with propidium
iodide (PI) in Vindelov’s cocktail (10 nM Tris–HCl, pH 8, 10 mM NaCl, 50 mg
PI/l, and 10 mg/l Ribonuclease A, and 0.1% Nonidet P-40). The stained cells
were analyzed in FACS Calibur flow cytometer (Becton Dickinson) with an
excitation wavelength of 488 nm. The resulting histograms were analyzed by
program MODFIT (Becton Dickinson) for cell distribution in cell cycle phases.
The average coefficient of variation (CV) is within 5%. Results are expressed
as mean ± SEM, n = 4Mixed properties of RU486 1981
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began after 12 h of treatment, and this was associated with the
concurrent accumulation of cells in the G0/G1 phase. There was
approximately 70% reduction of S-phase cells by 24 h. After 48 h of
treatment, the effects of both compounds began to diminish possibly
due to the depletion of the drugs. 
RU486 elicited distinct morphological changes and had
no effect on focal adhesion 
Although RU486 showed similar growth inhibitory activity as
progesterone in ABC28 cells, the morphological changes induced
by RU486 were distinct from those induced by progesterone. As
has been reported (Lin et al, 2000) that progesterone-treated cells
(Figure 4B) were considerably flattened and more spread than the
vehicle-treated controls (Figure 4A). In contrast, RU486-treated cells
showed the morphology of multipolar, stellate cells (Figure 4C).
Furthermore, progesterone-treated cells showed marked increase
in F-actin staining (stress fibers) (Figure 5C) and in focal adhesion
protein paxillin (Figure 5D, paxillin staining are regular white
spots at the tips of the stress fibers) as compared with vehicle-
treated controls (Figure 5A,B). On the other hand, RU486-treated
ABC28 cells showed little increase in the staining of stress fibers
or focal adhesions (Figure 5E, F). 
RU486 antagonized the effects of progesterone on cell
spreading and focal adhesion 
As compared with controls (Figure 4A), progesterone antagonist
ZK98299 had no effect on cell morphology (Figure 4D) but it
inhibited progesterone-mediated cell spreading (Figure 4E).
Similarly, RU486 was also a progesterone antagonist in inhibiting
the cell spreading induced by progesterone (Figure 4F), and the
cells took the morphology of that treated by RU486 alone. 
The antagonistic effect of RU486 on cell growth could not be
demonstrated in ABC28 cells since progesterone and RU486 are
almost of equivalent potency in this cell line. However, RU486 was
able to reverse some of the growth inhibitory effect of progesterone
in PR-transfectants ABC21 and ABC79 cells in which progesterone
was more potent than RU486. As is shown in Figure 6, RU486 inhib-
ited the cell growth of ABC21 and ABC79 cells in a concentration-
dependent manner. It also reversed the growth inhibitory effect of
progesterone in a concentration-dependent manner. The maximum
inhibition is up to the level that was achieved by RU486 alone. 
Progesterone inhibited the activation of p42/44 MAPK
whereas RU486 increased the activation 
p42/p44 MAPK function in a protein kinase cascade that plays
critical roles in the cell growth and differentiation. The activation
of these proteins is mediated by the phosphorylation of Thr/Tyr
residues. In order to understand the differences between proges-
terone- and RU486-mediated molecular pathways we studied the
regulation of activation of p42/p44 MAPK in the treated cells by
Western blotting analysis. As is shown in Figure 7 that both phos-
phorylated p42 and p44 MAPK are detectable but p42 MAPK is
the major protein detected in ABC28 cells. p44 MAPK is not
visible in the blot probed by anti-p42/44. Interestingly, while both
compounds inhibited the growth of ABC28 cells progesterone and
RU486 exhibited opposite regulatory roles on the activation of
p42/p44 MAPK. Progesterone inhibited the activation of p42/p44
MAPK by as much as 80% of the controls. The inhibition is
detectable at 1 h after treatment and the effect persisted for the
subsequent 48 h. In contrast, RU486 increased the activation of
p42/p44 MAPKs. The effect was notable after 8 h of treatment.
The activation continued to increase over time and by 72 h the
active p42/p44 MAPKs in RU486-treated cells was about 3-fold of
that in the controls. This clearly illustrates that RU486 and proges-
terone function via different molecular mechanisms in ABC28 cells. 
Effect of RU486 was mediated by PR 
The effect of RU486 on cell growth and morphology in ABC28
cells are mediated via PR since RU486 demonstrated no effect on
cell growth in PR-negative control transfectant CTC15 (Figure 8).
Furthermore, antiprogestin ZK98299 was able to reverse the
growth inhibitory effect of RU486 in ABC28 cells (Figure 8) in a
concentration-dependent manner. ZK98299 were also able to
reverse RU486-induced morphological changes (data not shown).
These data substantiate that RU486-induced growth inhibition and
morphological changes are mediated by PR. 
DISCUSSION 
ABC28 cells is one of the clones established by transfecting PR
cDNA into ER-α - and PR-negative breast cancer cells MDA-MB-
231 so that the functions of progesterone can be studied indepen-
dent of estrogens and ER. These cells proved to be an excellent
model for delineating the function of progesterone and its
analogues. Progesterone was shown to induce remarkable growth
inhibition and focal adhesion in the PR-transfected MDA-MB-231
cells ABC28 (Lin et al, 1999, 2000). 
RU486 has proved to be a remarkable antiprogesterone and
antiglucocorticoid agent in clinical applications since its birth
some 20 years ago (Cadepond et al, 1997; Herrmann et al, 1982;
Gaillard et al, 1983; Spitz and Chwalisz, 2000). In ABC28 cells,
RU486 demonstrated mixed properties. It was shown to be an
antagonist in that it inhibited progesterone-mediated cell growth
and focal adhesion. The compound was also a progesterone
agonist when used alone as it inhibited cell growth and arrested
cells in G0/G1 phase of the cell cycle like progesterone did.
Furthermore, RU486 showed unprogestin-like effect. It induced
the morphology of multipolar, stellate cells whereas progesterone
induced cell flattening and spreading in ABC28 cells. In addition,
RU486 had no progesterone-like effect on focal adhesion. 
More interestingly, the model revealed that RU486 and proges-
terone exerted their roles differentially at the molecular level in
ABC28 cells. p42/p44 MAPKs pathway is generally believed to be
the critical route between membrane-bound ras oncogenes and the
nucleus to transmit growth and differentiation signals (Hall, 1998;
Dent et al, 1998; Sebolt-Leopold, 2000). The activation of these
proteins is mediated by the phosphorylation of Thr/Tyr residues.
Although both compounds inhibited cell growth, RU486 markedly
upregulated the activation of p42/p44 MAPK whereas progesterone
inhibited the activation. The results indicate two interesting possibil-
ities. Firstly, since RU486-mediated activation of MAPK is not asso-
ciated with growth stimulation but growth inhibition, the p42/p44
MAPK pathway may not be a growth signal in MDA-MB-231 cells.
Secondly, the downstream of p42/p44 MAPK signaling may be defi-
cient in these cells and that is why it can not signal growth. The
results also indicate that RU486- and progesterone-mediated growth
inhibitions are mediated by different mechanisms. 
RU486-induced morphological changes are also related to
distinct molecular events as that of progesterone. RU486-induced1982 VC-L Lin et al
British Journal of Cancer (2001) 85(12), 1978–1986 © 2001 Cancer Research Campaign
A B
C D
E F
Figure 4 RU486 induced distinct morphological changes in ABC28 and it was able to reverse progesterone-induced cell spreading. Cells grown in 6-well
plates were treated with various compounds at 1 nM in 0.1% ethanol for 48 h before they were viewed and photographed under a Zeiss AXIOVERT 35 phase
contrast microscope. Progesterone (1 nM)-treated cells (B) are more flattened and spread than the vehicle-treated controls (A). RU486 (1 nM)-treated cells took
the morphology of multipolar, flattened stellate cells (C). RU486 at molar excess inhibited the cell spreading induced by progesterone (E). ZK98229 had no
effect alone (D) but inhibited progesterone-mediated cell spreading (F). Bar=100 µ M Mixed properties of RU486 1983
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Figure 5 Effect of progesterone and RU486 on the development of F-actin and formation of focal adhesion in ABC28 cells. ABC28 cells were treated with
various compounds at 1 nM for 48 h before they were stained with either FITC-phalloidin (A, C, E), or co-stained with both FITC-phalloidin and focal adhesion
protein paxillin mAb which was detected by FITC-conjugated secondary antibody (B, D, F). As compared with vehicle-treated controls (A, B), progesterone-
treated cells showed increased F-actin (C) and focal adhesions as identified by focal adhesion protein paxillin (D, paxillin staining are regular green spots at the
tips of F-actin). RU486-treated cells did not show any increase in F-actin or paxillin staining (E, F). Bar = 20 µ M1984 VC-L Lin et al
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Figure 6 RU486 was able to reverse progesterone-inhibited cell
proliferation in PR-transfected clones ABC21 and ABC79 in which RU486
was less potent than progesterone. RU486 with concentrations range from
10–12–10-6 M was incubated with cells alone, or with 10–9M progesterone for
48 h before the cells were determined for BrdUrd incorporation using ELISA
kit according to manufacturer’s instructions. Results are the means (n = 4) of
percentage of vehicle-treated controls
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Figure 7 RU486 enhanced the activation of p42/p44 MAPKs whereas progesterone inhibited the activation in ABC28 cells. ABC28 cells were treated with 
0.1 µ M RU486, 0.1 µ M progesterone or control vehicle (0.1% ethanol) for the indicated periods of time. Whole cell lysate were collected. 20 µ g of protein was
analysed by Western blotting. Following detection of active p42/44 MAPK by antibody against phosphorylated p42/44 MAPK (ERK 1 and 2), the membrane was
stripped and re-probed with anti-p42/p44 MAPKs antibodies to determine the amount of total MAPK. A Immunoblot of phosphorylated and total p42/p44
MAPKs. B Densitometric data of the immunoblot shown in A. The relative amount of activated p42/p44 MAPKs was normalized against the total MAPKs at each
time point. The activated p42/p44 MAPKs in the drug-treated groups were expressed as the percentage of vehicle-treated controls
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Figure 8 Antiprogestin ZK98299 was able to reverse the growth inhibitory
effect of RU486 in PR-transfectant ABC28 cells and but showed no effect in
control transfectant CTC15. Cells (3000) were plated onto 96-well plates in
phenol red-free DMEM supplemented with 5% DCC-FCS. ZK98299-
containing medium was added to the cells two days later at various
concentrations in 0.1% ethanol. BrdUrd incorporation was measured 48 h
later by ELISA according to manufacturer’s instructions. Results are the
means (n = 4) of percentage of vehicle-treated controlsMixed properties of RU486 1985
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morphological changes are not associated with increases in the
assembly of stress fibres and formation of focal adhesions. In
contrast, progesterone-treated cells exhibited a striking increase of
stress fibres both in number and diameter, and increased focal
contacts as shown by the increase of the staining of paxillin. As
was reported in detail previously (Lin et al, 2000) progesterone-
induced focal adhesions were associated with distinct increases in
tyrosine phosphorylation of focal adhesion protein paxillin and
focal adhesion kinase (FAK). The assembly of contractile actin
filaments and the associated focal adhesion complexes are gener-
ally believed to be activated by a Rho signaling pathways (see
review in Hall, 1998). 
Several studies have suggested mechanisms by which steroid
antagonists inappropriately activate transcription. Cross-talk between
antagonist-occupied steroid receptor and cell surface signaling path-
ways such as the activation of PKA and PKC pathways can switch
the antagonist into an agonist (Beck et al, 1996; Sartorius et al, 1994).
More recent studies revealed that antagonist-occupied steroid recep-
tors are the targets for the action of endogenous coregulators (Jackson
et al, 1997; Simth et al, 1997; Takimoto et al, 1999). The antagonistic
effect involves the recruitment of corepressors whereas the binding
of coactivators to the receptor-antagonist complexes may result in the
exhibition of partial agonist activity. There is also evidence to indi-
cate that RU486-PR complexes may interact with non-PRE
sequence. For example, Tung et al (1993) demonstrated using tran-
scription assays that RU486-occupied PR-B was able to activate gene
transcription through non-PRE DNA binding sites. Since RU486 is
known to be capable of inducing high affinity association of PR with
target DNA (El-Ashry et al, 1989; Guiochon-Mantel et al, 1988), it is
an interesting possibility that RU486 may also induce a strong asso-
ciation of PR with non-target sequences and subsequently activate
‘unprogestin’-like transcription in ABC28 cells. 
It is also interesting to note that the functions of progesterone and
RU486 can be differentially mediated by two PR isoforms that
arise from the same gene and function to exhibit different transcrip-
tion regulatory activities in vitro and in vivo (Conneely et al, 2001;
Fuhrmann et al, 2000). In the presence of cAMP, RU486 can
exhibit inappropriate gene activation in T47D subline expressing
PR isoform B but not in cells expressing isoform A (Sartovius et al,
1994). It was proposed that PR-B has a unique third transactivation
domain that may confer agonist-like properties in the presence of
antiprogestin, whereas PR isoform A exhibits transdorminant nega-
tive activity toward PR isoform B (Horwitz et al, 1995). 
In summary, the study revealed the mixed properties of RU486
in PR-transfected MDA-MB-231 breast cancer cells and that some
of the properties are ‘unprogestin’-like. The signaling pathways
mediated by RU486 and progesterone also appeared to be
different. It is clinically important to identify these inappropriate
side effects of an antagonist. PR-transfected cells ABC28 is an
excellent model for studying the functions and for identifying side
effects of progesterone receptor modulators as these cells are very
sensitive to progestins and antiprogestins. 
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